The Chief Executive Officer (CEO), Karlheinz Gast of APONTIS PHARMA AG has informed the Supervisory Board that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board. The Supervisory Board received and accepted Mr. Gast’s resignation at its extraordinary meeting on July 10, 2023. The service agreement with Mr. Gast will be canceled.

At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date of 1 September 2023. Until then, Executive Board member Thomas Milz will head the company alone. Mr. Wohlschlegel (56) brings more than 26 years of experience in the pharmaceutical industry.

He was Managing Director of Merck Serono GmbH until 2021 and responsible for the European business of Merck KGaA before that. Mr. Wohlschlegel is a recognized leader with an outstanding strategic and operational track record.